Publications by authors named "Borje S Andersson"

100Publications

Letter to the Editor Regarding "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement".

Biol Blood Marrow Transplant 2020 Sep 11;26(9):e232-e234. Epub 2020 May 11.

Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.03.022DOI Listing
September 2020

Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells.

Exp Hematol 2020 01 15;81:32-41. Epub 2020 Jan 15.

Department of Stem Cell Transplantation & Cellular Therapy, University of Texas M. D. Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2020.01.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023992PMC
January 2020

CMV-Reactive NK Cells in Pediatric Post-Hematopoietic Stem Cell Transplant.

Transplant Proc 2020 Jan - Feb;52(1):353-359. Epub 2019 Dec 20.

Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transproceed.2019.11.010DOI Listing
July 2020

Bayesian non-parametric survival regression for optimizing precision dosing of intravenous busulfan in allogeneic stem cell transplantation.

J R Stat Soc Ser C Appl Stat 2019 Apr 16;68(3):809-828. Epub 2018 Dec 16.

Department of Stem Cell Transplantation and Cellular Therapy, U.T. M.D. Anderson Cancer Center, Houston, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/rssc.12331DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714050PMC
April 2019

Pharmacokinetics: Unique Challenges in Blood Monitoring for Oncology Nurses.

Clin J Oncol Nurs 2019 04;23(2):191-196

University of Texas Health Sciences Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1188/19.CJON.191-196DOI Listing
April 2019

Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells.

Exp Hematol 2018 11 10;67:49-59.e1. Epub 2018 Aug 10.

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2018.08.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262883PMC
November 2018

Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia.

Biol Blood Marrow Transplant 2018 07 12;24(7):1514-1520. Epub 2018 Feb 12.

Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.02.003DOI Listing
July 2018

Viral-specific T-cell response in hemorrhagic cystitis after haploidentical donor stem cell transplantation.

Transpl Infect Dis 2017 Dec 25;19(6). Epub 2017 Oct 25.

Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/tid.12775DOI Listing
December 2017

Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review.

Expert Opin Drug Metab Toxicol 2017 Sep 17;13(9):901-923. Epub 2017 Aug 17.

b Department of Stem Cell Transplantation , The University of Texas M.D. Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17425255.2017.1360277DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584057PMC
September 2017

Development of an assay for cellular efflux of pharmaceutically active agents and its relevance to understanding drug interactions.

Exp Hematol 2017 08 4;52:65-71. Epub 2017 May 4.

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2017.04.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522632PMC
August 2017

The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.

Leuk Lymphoma 2017 11 10;58(11):2705-2716. Epub 2017 Apr 10.

a Department of Stem Cell Transplantation and Cellular Therapy , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1306647DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5526721PMC
November 2017

Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells.

Leuk Res 2016 08 27;47:100-8. Epub 2016 May 27.

Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2016.05.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961533PMC
August 2016

Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells.

Leuk Lymphoma 2016 11 16;57(11):2644-52. Epub 2016 Mar 16.

b Department of Stem Cell Transplantation and Cellular Therapy , UT MD Anderson Cancer Center , Houston , TX , USA ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2016.1157871DOI Listing
November 2016

Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study.

Exp Hematol 2016 06 11;44(6):458-65. Epub 2016 Mar 11.

Department of Stem Cell Transplantation & Cellular Therapy, University of Texas M. D. Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2016.03.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864055PMC
June 2016

Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.

J Natl Cancer Inst 2016 Mar 18;108(3). Epub 2015 Nov 18.

Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ (YW, VTC); Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China (FY, YS, WZ, XG); Department of Medicine, University of Chicago, Chicago, IL (JW); Section of Hematology/Oncology, VA New Jersey Health Care System, East Orange, NJ (VTC); Department of Stem Cell Transplantation and Cellular Therapy (BSA, MHQ, REC) and Department of Lymphoma/Myeloma (MLW), The University of Texas MD Anderson Cancer Center, Houston, TX; Institute for Myeloma & Bone Cancer Research, West Hollywood, CA (JRB).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv342DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280981PMC
March 2016

Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia.

Biol Blood Marrow Transplant 2016 Jan 4;22(1):47-53. Epub 2015 Sep 4.

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas; Transplant Myeloid Study Group, Department of Stem Cell Transplant and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2015.08.031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892364PMC
January 2016

Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.

Exp Hematol 2015 Jun 19;43(6):448-61.e2. Epub 2015 Feb 19.

Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2015.02.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4458397PMC
June 2015

Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation?

Biol Blood Marrow Transplant 2015 Apr 23;21(4):713-9. Epub 2014 Dec 23.

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2014.12.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359638PMC
April 2015

Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.

J Clin Oncol 2014 Nov 29;32(31):3497-505. Epub 2014 Sep 29.

Christopher G. Kanakry, Marta Medeot, Richard J. Jones, Leo Luznik, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD; Paul V. O'Donnell, Terry Furlong, Marco Mielcarek, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcos J. de Lima, Wei Wei, Richard E. Champlin, Peter F. Thall, Borje S. Andersson, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2013.54.0625
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.54.0625DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209101PMC
November 2014

Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.

Biol Blood Marrow Transplant 2014 Nov 9;20(11):1687-95. Epub 2014 Aug 9.

Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2014.08.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002996PMC
November 2014

Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival time.

Biol Blood Marrow Transplant 2014 Aug 13;20(8):1139-44. Epub 2014 Apr 13.

Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2014.04.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099297PMC
August 2014

The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.

Leuk Lymphoma 2014 Jul 4;55(7):1625-34. Epub 2014 Feb 4.

Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M. D. Anderson Cancer Center , Houston, TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2013.856007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320642PMC
July 2014

High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma.

Biol Blood Marrow Transplant 2013 Jun 16;19(6):991-4. Epub 2013 Mar 16.

Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2013.03.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411554PMC
June 2013

Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation.

Pharmacogenomics 2013 Jan;14(1):75-87

Experimental Cancer Medicine (ECM), Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs.12.185DOI Listing
January 2013

Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines.

Exp Hematol 2012 Oct 9;40(10):800-10. Epub 2012 Jun 9.

Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2012.06.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3447105PMC
October 2012

Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines.

Leuk Lymphoma 2012 May 6;53(5):973-81. Epub 2011 Dec 6.

Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M. D. Anderson Cancer Center, Houston, TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2011.634043DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867126PMC
May 2012

Busulfan and metronidazole: an often forgotten but significant drug interaction.

Ann Pharmacother 2011 Jul 5;45(7-8):e39. Epub 2011 Jul 5.

Division of Pharmacy, MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1345/aph.1Q087DOI Listing
July 2011

Advances in CML: The role of allogeneic hematopoietic stem cell transplantation.

Clin Adv Hematol Oncol 2010 Nov;8(11):746-8

Department of Stem Cell Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
November 2010

Unrelated donor transplantation for acute myelogenous leukemia in first remission.

Biol Blood Marrow Transplant 2011 Jul 16;17(7):1067-71. Epub 2010 Nov 16.

Department of Stem Cell Transplantation and Cellular Therapy, U.T. M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2010.11.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4080632PMC
July 2011

Generic immunosuppressants in hematopoietic cell transplantation.

Biol Blood Marrow Transplant 2011 Mar 16;17(3):285-90. Epub 2010 Nov 16.

Hematologic Malignancies and Stem Cell Transplantation, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2010.11.006DOI Listing
March 2011

The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling.

Biochem Pharmacol 2011 Jan 8;81(2):222-32. Epub 2010 Oct 8.

Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00062952100075
Publisher Site
http://dx.doi.org/10.1016/j.bcp.2010.09.027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3006064PMC
January 2011

Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.

Environ Mol Mutagen 2010 Jul;51(6):659-68

Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/em.20603
Publisher Site
http://dx.doi.org/10.1002/em.20603DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346159PMC
July 2010

Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation.

Biol Blood Marrow Transplant 2010 Apr 29;16(4):555-9. Epub 2010 Jan 29.

Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S108387910900600
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2009.12.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352934PMC
April 2010

5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis.

Leuk Res 2010 Mar 3;34(3):364-72. Epub 2009 Sep 3.

Department of Stem Cell Transplantation and Cellular Therapy, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2009.08.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2823987PMC
March 2010

Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia.

Curr Opin Oncol 2009 Jun;21 Suppl 1:S11-5

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=00001622-200906001-000
Publisher Site
http://dx.doi.org/10.1097/01.cco.0000357469.83960.12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037323PMC
June 2009

Busulfan in hematopoietic stem cell transplantation.

Biol Blood Marrow Transplant 2009 May 12;15(5):523-36. Epub 2009 Feb 12.

University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S108387910801100
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2008.12.489DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4261695PMC
May 2009

Altered gene expression in busulfan-resistant human myeloid leukemia.

Leuk Res 2008 Nov 12;32(11):1684-97. Epub 2008 Mar 12.

Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2008.01.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2633244PMC
November 2008

Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule.

Biol Blood Marrow Transplant 2007 Jan;13(1):56-64

Pharmaceutical Development Center, The University of Texas MD Anderson Cancer Center, Houston, Texas 770554, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2006.08.037DOI Listing
January 2007

Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.

Blood 2006 Aug 6;108(4):1421-3. Epub 2006 Apr 6.

Department of Blood and Marrow Transplantation, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2006-02-001933DOI Listing
August 2006

Model studies of cyclophosphamide resistance in human myeloid leukemia.

Cancer Treat Res 2002 ;112:211-35

Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4615-1173-1_11DOI Listing
May 2003